The Dutch Biomarker Development Center (BDC) is an initiative of the University of Groningen (RUG), the University Medical Center Groningen (UMCG), the Erasmus Medical Center Rotterdam (EMC), the Radboud University Medical Center Nijmegen (RUMC) and Netherlands Organisation for Applied Scientific Research (TNO). The BDC focuses on biomarker verification and validation in a multi-centric setting involving technology-oriented and clinical centers. The major disease areas are Chronic Obstructive Pulmonary Disease (COPD), Diabetes Type II and Alzheimer’s Disease.
LC-MS method to quantify sRAGE
BDC researchers at the University of Groningen have developed a validated LC-MS method to quantify the COPD biomarker sRAGE in serum. The method is based on sRAGE enrichment using affimers, a novel type of affinity ligand that is not based on antibodies. The work has been published in the Journal of Proteome Research. Read the article here. (Posted on 21 July 2018)
New avenues to biomarkers for cervical cancer
A collaboration between the BDC groups at the Erasmus Medical Center in Rotterdam and the University of Groningen led to new insights into molecular changes in squamous cell cervical carcinoma tissue. This work opens new avenues for developing better biomarkers to assess whether early lesions progress to cervical cancer or not. See the article here (Posted on 16 May 2018)
National Xomics platform
The Biomarker Development Center (BDC) is member of the national Xomics (speak Crossomics) platform, which combines proteomics, genomics and metabolomics. Data integration is a major focus of this platform, since new insights into biological and pathophysiological mechanisms and more sensitive and specific biomarker (panels) can only be obtained by understanding the underlying biology at all levels. More details about this initiative can be found here. (Posted on 15 April 2018)
Developing novel methods for protein, peptide and metabolite analysis: an interview with Rainer Bischoff
Rainer Bischoff, Professor of Analytical Biochemistry at the University of Groningen (Groningen, The Netherlands), talks to Sankeetha Nadarajah, Managing Commissioning Editor (Bioanalysis), regarding the development of novel methods for protein, peptide and metabolite analysis. This interview was recorded at the European Biotechnology Forum (EBF) symposium in Barcelona (Spain). You can find the interview here.
Traversing Omics: How Mass Spectrometry Advances Translational Medicine
Professor van Gool's laboratory at Radboudumc specializes in the metabolic side of disease, focusing on proteins, metabolites and enzyme functions, and combines this with insights from Radboudumc's genetic analysis to deliver comprehensive molecular diagnostics. See full report here. (Posted on 21 January 2018)